CORE-006: BEHAVORIAL MEASUREMENT SHARED RESOURCE (BMSR) PROJECT SUMMARY / ABSTRACT The Behavioral Measurement Shared Resource (BMSR) provides expert assistance and services for integrating behavioral and epidemiological research into the research goals of the OSUCCC. The BMSR maintained a high level of usage over the last grant period and provided, or is currently providing, key support for several increasingly large NCI-funded projects and OSUCCC initiatives. It is directed by Dr. Paul Reiter (CC) and the Senior Faculty Advisor is Dr. Michael Slater (CC). The BMSR offers services in five primary areas: 1) research design; 2) behavioral and survey assessment; 3) participant recruitment, accrual and retention; 4) data collection (both quantitative and qualitative data); and 5) population-based data retrieval. Thus, the BMSR provides a continuum of services for research projects, ranging from planning and development of research proposals and projects through data collection and the interpretation of research data.
The Specific Aims are to: 1) provide expertise in research design and behavioral and survey assessment; 2) assist investigators with participant recruitment, accrual and retention to ensure the inclusion of research participants that are broadly representative of the target population(s); and, 3) provide expertise and services for the collection and management of both quantitative and qualitative research data. The BMSR supports increasingly complex studies including population-based cohort studies, universal consenting for all OSUCCC patients into the Total Cancer Care protocol for biobanking, and the statewide colorectal cancer initiative accruing cancer patients and their families across the state of Ohio. Over the last five years, the BMSR supported investigators from all 5 research programs an, contributed to 58 publications and provided services to over 10 NCI funded grants, including 2 NCI P50 Centers. Future plans for the BMSR are to offer support with call management software; ecological momentary assessment (EMA); gain expertise in additional online data collection software programs including mobile applications; and, offering the use of geographic information systems (GIS) software. The BMSR leverages extensive institutional support and seeks only 9.5% support from CCSG funds. The Behavioral Measurement Shared Resource is part of the Quantitative Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-40
Application #
9000505
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
$67,601
Indirect Cost
$23,704
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications